Bridget Hodkinson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/172547/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Circulating Cytokine Profiles and Their Relationships with Autoantibodies, Acute Phase Reactants, and Disease Activity in Patients with Rheumatoid Arthritis. Mediators of Inflammation, 2010, 2010, 1-10.	3.0	41
2	South African recommendations for the management of rheumatoid arthritis: An algorithm for the standard of care in 2013. South African Medical Journal, 2013, 103, 576.	0.6	34
3	Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. BMC Musculoskeletal Disorders, 2015, 16, 130.	1.9	27
4	Immunochip Identifies Novel, and Replicates Known, Genetic Risk Loci for Rheumatoid Arthritis in Black South Africans. Molecular Medicine, 2014, 20, 341-349.	4.4	21
5	HLA-DRB1 shared epitope genotyping using the revised classification and its association with circulating autoantibodies, acute phase reactants, cytokines and clinical indices of disease activity in a cohort of South African rheumatoid arthritis patients. Arthritis Research and Therapy, 2011, 13, R160.	3.5	20
6	Combination leflunomide and methotrexate in refractory rheumatoid arthritis: a biologic sparing approach. Therapeutic Advances in Musculoskeletal Disease, 2016, 8, 172-179.	2.7	20
7	The diagnostic utility of the anti-CCP antibody test is no better than rheumatoid factor in South Africans with early rheumatoid arthritis. Clinical Rheumatology, 2010, 29, 615-618.	2.2	16
8	Rheumatoid arthritis in the developing world: stepping up to the challenge. Clinical Rheumatology, 2014, 33, 1195-1196.	2.2	13
9	Biologic therapy for rheumatoid arthritis in developing countries–a place for non-TNF inhibitors as first-line treatment?. Rheumatology, 2015, 54, 208-209.	1.9	11
10	Tight control of rheumatoid arthritis in a resource-constrained setting: a randomized controlled study comparing the clinical disease activity index and simplified disease activity index. Rheumatology, 2015, 54, 1033-1038.	1.9	10
11	Navigating COVID-19 in the developing world. Clinical Rheumatology, 2020, 39, 2039-2042.	2.2	10
12	Points to consider in cardiovascular disease risk management among patients with rheumatoid arthritis living in South Africa, an unequal middle income country. BMC Rheumatology, 2020, 4, 42.	1.6	10
13	Comparison of the diagnostic potential of three anti-citrullinated protein antibodies as adjuncts to rheumatoid factor and CCP in a cohort of South African rheumatoid arthritis patients. Rheumatology International, 2018, 38, 993-1001.	3.0	7
14	HLA-DRB1 Amino Acid Positions and Residues Associated with Antibody-positive Rheumatoid Arthritis in Black South Africans. Journal of Rheumatology, 2019, 46, 138-144.	2.0	6
15	Pitfalls in the assessment of smoking status detected in a cohort of South African RA patients. Rheumatology International, 2016, 36, 1365-1369.	3.0	5
16	Diagnostic utility of, and influence of tobacco usage and genetic predisposition on, immunoglobulin A, rheumatoid factor and anti-citrullinated peptide auto-antibodies in South African rheumatoid arthritis patients. African Health Sciences, 2018, 18, 295-303.	0.7	3